Best of ASCO - 2014 Annual Meeting

 

Welcome

Soft Tissue

Sarcoma

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
10-year follow-up results of perioperative chemotherapy with doxorubicin (DXR) and ifosfamide (IFM) for high-grade soft tissue sarcomas (STS) in the extremities: Japan Clinical Oncology Group study JCOG0304.

Kazuhiro Tanaka

e22533

A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib (REG) in patients (pts) with nonadipocytic soft tissue sarcoma (STS) previously treated with pazopanib (PAZ).

Nicolas Penel

11021

A novel HMGA2-YAP1 fusion gene in a patient with aggressive angiomyxoma.

Brandon Dasilva

e22514

A novel approach to neoadjuvant chemoradiation for soft tissue sarcoma using cisplatin and adriamycin.

Ashley Brown

e22515

A phase I/II investigation of nivolumab and ABI-009 (nab-sirolimus) in advanced undifferentiated pleomorphic sarcoma (UPS), liposarcoma (LPS), chondrosarcoma (CS), osteosarcoma (OS), and Ewing sarcoma: Preliminary efficacy and safety results.

Erlinda Maria Gordon

11057

A phase I/II study of pembrolizumab (Pem) and doxorubicin (Dox) in treating patients with metastatic/unresectable sarcoma.

Seth Pollack

11009

A phase II randomized study of CMB305 and atezolizumab versus atezolizumab in NY-ESO-1+ soft tissue sarcoma: Analysis of immunogenicity, tumor control, and patient survival.

Sant P. Chawla

11011

A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated Classic Kaposi sarcoma (CKS).

Alona Zer

11064

A phase II study of ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.

Brian Andrew Van Tine

TPS11079

A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma.

Ciara Marie Kelly

11049

A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-STS 0415).

Viktor Grünwald

TPS11075

A single-center retrospective study of patients treated with trabectedin (TRB) with long-term follow up.

Brett A. Schroeder

11061

ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial.

Andrew J. Wagner

11005

Activity of chemotherapy in inflammatory myofibroblastic tumor (IMT): A retrospective analysis within the Italian Rare Tumours Network (RTR).

Giacomo Giulio Baldi

e22545

Activity of hormonal treatment in uterine smooth muscle tumors of uncertain malignant potential (STUMP): A mono-institutional referral center experience in advanced disease.

Roberta Sanfilippo

11066

Activity of sirolimus in advanced epithelioid hemangioendothelioma (EHE): A retrospective analysis within the Italian Rare Tumor Network (RTR).

Noemi Simeone

11065

Advanced epithelioid haemangioendotelioma: Fever, pain, and pleural effusion predict a worse outcome.

Bruno Vincenzi

e22540

Alveolar soft PART sarcomas (ASPS): A tertiary care center experience from India.

Vijai Simha

e22553

Angiosarcoma of bone: A European Muscoloskeletal Oncology Society (EMSOS) multicenter, retrospective study.

Emanuela Palmerini

11046

Angiosarcoma treated with checkpoint inhibitors: A single-institution experience.

Vaia Florou

e22543

ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).

William D. Tap

LBA3

Apatinib for epithelioid sarcoma: analysis on eight advanced stage cases in a single institute.

Yong Chen

e22551

ARST1321: Pazopanib neoadjuvant trial in non-rhabdomysarcoma soft tissue sarcomas: A report of major wound complications.

Thomas Scharschmidt

11059

Benefit of intensified perioperative chemotherapy within high-risk CINSARC patients with resectable soft tissue sarcomas (CIRSARC).

Antoine Italiano

TPS11078

Cardio-toxicity among patients with sarcoma: A Cardio-Oncology Registry.

Sivan Shamai

e22530

CBT-1 in combination with doxorubicin in patients with metastatic, unresectable sarcomas who previously progressed on doxorubicin.

Gregory Michael Cote

TPS11077

Chinese largest cohort data from NCT03120846: Efficacy and safety of VEGFR2 inhibitor apatinib for metastatic soft tissue sarcomas.

Jilong Yang

e22532

Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.

Melissa Amber Burgess

11015

Clinical benefit of next generation sequencing in soft tissue and bone sarcoma: Rush University Medical Center’s experience.

Mia C. Weiss

e22552

Clinical features and prognosis of patients with liposarcoma: Single-center experience.

Metin Demir

e22557

Clinical outcomes from a retrospective registry of patients with locally advanced/metastatic synovial sarcoma and myxoid round cell liposarcoma.

Steven Attia

e22520

Clinical outcomes of sunitinib (Su) for patients (pts) with desmoid tumors (DT).

Salvatora tindara Miano

11052

Clinical presentation, natural history and therapeutic approach in patients with solitary fibrous tumor: A retrospective analysis.

Patrick Schoffski

e22522

Clinicopathological prognostic and predictive factors of malignant peripheral nerve sheath tumors (MPNST) survival and treatment efficacy.

Pawel Sobczuk

e22537

Comparative DNA cytometry of primary and recurrent soft tissue sarcomas.

Irina Dashkova

e22516

Complete remission of patients with heavily pretreated uterine sarcomas by weekly bevacizumab and temozolomide.

Kazuki Takasaki

11051

Copy number variations of apoptosis-regulating genes and MKI67 gene in primary and recurrent soft tissues sarcomas.

Tatiana V. Ausheva

e22517

Desmoid tumor (DT) management in dedicated sarcoma medical oncology clinic in a developing country: Lessons learnt.

Sameer Rastogi

e22541

Determinants of secondary alterations in WWTR1-CAMTA1 fusion epithelioid hemangioendothelioma.

Nathan David Seligson

11045

DNA damage response pathway alterations and clinical outcome in leiomyosarcoma.

Evan Rosenbaum

11048

Does the addition of chemotherapy to neoadjuvant radiotherapy impact survival in high-risk extremity and trunk soft tissue sarcoma?

Mudit Chowdhary

11054

Efficacy and dosimetry prognostic factors of image guided 125I seed implantation for locally recurrent soft tissue sarcoma.

Weijuan Jiang

11073

Efficacy and safety of anlotinib in advanced soft tissue sarcoma: results from one of multi-centers in a phase IIB trial (ALTER0203).

Lina Tang

e22518

Efficacy of low dose pazopanib in advanced soft tissue sarcoma (STS): Experience from a dedicated sarcoma medical oncology clinic in India.

Santosh Kumar C

e22555

Exploration of tumor genetic alterations and associations with clinical outcomes: Retrospective genomic analysis of archived liposarcoma (LPS) and leiomyosarcoma (LMS) samples from phase III trial of trabectedin (T) versus dacarbazine (D).

Shibu Thomas

11019

Exploring ceramide metabolism as a potential target in dedifferentiated liposarcoma.

Bryce Demoret

e22558

Frequent mutations of genes predisposing to Rho GTPase signal activation and autophagy inhibition in metastatic soft tissue sarcoma unveiled by paired somatic and germline genomic analyses.

Katsuhito Takahashi

11071

Histone H3 modifying genes may serve as a predictive marker for metastasis in synovial sarcoma.

Achal Awasthi

11058

Identification of genomic alterations by circulating tumor DNA in leiomyosarcoma: A molecular analysis of 73 patients.

Junaid Arshad

11044

Immune signature and molecular profiling of radiation-induced sarcoma (RIS).

Eoghan Ruadh Malone

11040

Immunological and mutational characterization of non-uterine leiomyosarcoma: A pilot study.

Katarzyna Seliga

e22529

Improved local relapse-free and overall survival with secondary surgery after a first R1 or R2 resection in soft tissue sarcoma (STS) of the limbs or trunk wall: An analysis 10,931 patients (pts) in NETSARC.

Francois Gouin

11056

Incidence and prevalence of synovial sarcoma in the US: An analysis using SEER*Stat.

Nedra Joseph

e22535

Is PAX3-FOXO1 associated with worse outcome in adults with rhabdomyosarcoma (RMS)?

Sheena Guram

e22525

Low-dose chemotherapy with methotrexate and vinblastine for patients with refractory desmoid tumors: A second report of relationship between efficacy and various factors.

Yoshihiro Nishida

11050

MDM2 inhibitor AMG-232 and radiation therapy in treating patients with soft tissue sarcoma with wild-type TP53: A phase IB study (NRG-DT001).

Meng XU WELLIVER

TPS11076

Metagenomic discovery of a distinct inflammatory subtype of human angiosarcoma associated with human herpesvirus 7.

Jason Yongsheng Chan

11047

Molecular characterization and management of secondary resistance to serial TRK inhibitors.

Michael Nathenson

e22547

Multicenter phase II trial of pazopanib (P) in patients with angiosarcoma (AS).

Margaret von Mehren

11039

Multi-institutional european single-arm phase II trial of pazopanib in advanced typical solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study.

Josefina Cruz Jurado

11038

Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Final results of a randomized clinical trial from the Italian Sarcoma Group, the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG).

Alessandro Gronchi

11000

No relevant activity of olaratumab in patient-derived soft tissue sarcoma xenografts selected for expression of platelet-derived growth factor receptor a.

Jasmien Cornillie

e22556

Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma: Data of real-world utilization in Austria.

Florian Kocher

e22550

Outcome of patients with refractory malignant peripheral nerve sheath tumors (MPNST) enrolled on phase 2 trials.

Srivandana Akshintala

e22534

Outcomes of advanced angiosarcoma and hemangioendothelioma on propranolol based regimens from sarcoma medical oncology clinic in North India.

Naresh G

e22539

Pathologic discordance in sarcomas: Prospective comparison of external and sarcoma center pathologic diagnosis.

Mark A. Eckardt

11020

Pathologic response rates after neoadjuvant therapy for sarcoma.

Gautam A. Shrivastava

11060

Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): Long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies.

Hans Gelderblom

11042

Phase 1 combination therapy with pexidartinib (PEX) and sirolimus (S) to target tumor-associated macrophages in pigmented villonodular synovitis, malignant peripheral nerve sheath tumors, and other soft tissue sarcomas.

Gulam Abbas Manji

11055

Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma.

Mark Andrew Dickson

11004

Phase I/II clinical trial of NY-ESO-1-specific TCR-engineered T-cell transfer combined with a novel T-cell stimulator CHP:NE1 for patients with refractory soft tissue sarcoma.

Mikiya Ishihara

TPS11074

Phase II trial of gemcitabine (G) with pazopanib (P) or gemcitabine with docetaxel (T) in advanced soft tissue sarcoma (STS).

Neeta Somaiah

11008

Pilot study of NKTR214 and nivolumab in patients with sarcomas.

Sandra P. D'Angelo

11010

Precision oncology in sarcoma drug development: Impact of genomic matching on response, clinical benefit, and survival in sarcoma patients on phase 1 trials.

Shiraj Sen

11018

Preoperative chemoradiation +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): A report from Children's Oncology Group (COG) and NRG Oncology.

Aaron R. Weiss

11002

Prevalence of symptom clusters among sarcoma patients in active treatment.

Vanessa C. Copeland

e22561

Profiling of targetable aberrations in advanced sarcoma.

Muhammad Saad Hamid

e22559

Prognostic factors and therapeutic options for epithelioid hemangioendothelioma (EHE): A multicenter analysis of a series of fifty-seven cases.

Aurore Vozy

11062

Prognostic implications of tumor associated macrophages (TAMs) in soft tissue sarcoma.

Shailaja KS Raj

e22548

Renal Ewing's sarcoma: A single institute experience of seven patients.

Sorun Shishak

e22538

Results of the dose-finding phase of ARST 1321 from the Children's Oncology Group and NRG Oncology: Neoadjuvant chemoradiation or radiation therapy +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcomas.

Yen-Lin Chen

11070

Retroperitoneal soft tissue sarcoma (RPS): Recent outcome improvement and refinement of treatment strategies at a single institution.

Marco Fiore

11041

Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma.

Jomjit Chantharasamee

11072

Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950).

Silvia Stacchiotti

11003

SAINT: Results of a phase 1/2 study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.

Erlinda Maria Gordon

11016

Sarcopenia (SMI(+)) in patients (pts) with advanced or metastatic soft tissue sarcoma (a/mSTS): Potential parameter for risk prediction during multimodal therapy (MT)?

Dennis Strassmann

11069

Solitary fibrous tumor: A Brazilian cohort analysis.

Marcelle Goldner Cesca

11068

STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma.

Sylvie Bonvalot

11001

Successful generation of patient-derived xenografts and cell lines as preclinical models for sarcomas.

Tadashi Kondo

e22549

Survival and signals of response in advanced sarcoma patients enrolled on phase 1 trials in the era of precision oncology and novel immunotherapies.

Shiraj Sen

11063

Survival outcomes following cytoreductive nephrectomy (CN) in patients with metastatic renal cell sarcomas (MRCS).

Midhun Malla

e22519

Systemic therapy in advanced dermatofibrosarcoma protuberans: Imatinib and beyond.

Anshul Gupta

e22523

The importance of surgical margins in dedifferentiated liposarcoma survival.

Sara Albagoush

e22528

The phase Ib result of the safety and efficacy of lenvatinib (lenv) plus eribulin (eri) in advanced adipocytic sarcoma (LPS) and leiomyosarcoma (LMS): LEADER study (NCT03526679).

Tom Wei-Wu Chen

e22524

Translational study associated to a phase II study evaluating the activity of pazopanib in patients (pts) with advanced/metastatic liposarcoma (LPS): A joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) study.

Claudia Maria Valverde Morales

11067

Treatment of soft tissue sarcoma with a novel cold plasma jet.

Xiaoqian Cheng

e22562

Use of cardioprotective dexrazoxane and myelotoxicity in anthracycline-treated soft tissue sarcoma patients.

Marianna Silletta

11053

Work productivity loss in patients with tenosynovial giant cell tumors in the United States.

Feng Lin

e22527